These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

75 related items for PubMed ID: 21809229

  • 1. [Ex-vivo-chemoresponse testing of head and neck cancer: an old hat?].
    Wichmann G, Körner C, Dietz A.
    Laryngorhinootologie; 2011 Aug; 90(8):464-8. PubMed ID: 21809229
    [Abstract] [Full Text] [Related]

  • 2. [Preclinical models to establish innovative therapy strategies : Ex‑vivo assessment of head and neck tumor chemo- and immune responses].
    Wichmann G, Dietz A.
    HNO; 2016 Jul; 64(7):460-9. PubMed ID: 27259639
    [Abstract] [Full Text] [Related]

  • 3. Ex vivo responsiveness of head and neck squamous cell carcinoma to vinorelbine.
    Dollner R, Granzow C, Tschop K, Dietz A.
    Anticancer Res; 2006 Jul; 26(3B):2361-5. PubMed ID: 16821617
    [Abstract] [Full Text] [Related]

  • 4. The impact of stromal cell contamination on chemosensitivity testing of head and neck carcinoma.
    Dollner R, Granzow C, Helmke BM, Ruess A, Schad A, Dietz A.
    Anticancer Res; 2004 Jul; 24(1):325-31. PubMed ID: 15015616
    [Abstract] [Full Text] [Related]

  • 5. In vivo/ex vivo and in situ assays used in cancer research: a brief review.
    Teicher BA.
    Toxicol Pathol; 2009 Jan; 37(1):114-22. PubMed ID: 19098118
    [Abstract] [Full Text] [Related]

  • 6. [Pharmacological characterization of head and neck cancer in ex-vivo tests].
    Wichmann G, Dietz A.
    HNO; 2011 Sep; 59(9):866-73. PubMed ID: 21847640
    [Abstract] [Full Text] [Related]

  • 7. Heterogeneity of epithelial and stromal cells of head and neck squamous cell carcinomas in ex vivo chemoresponse.
    Horn IS, Wichmann G, Mozet C, Dietz A, Dollner R, Tschöp K, Boehm A.
    Cancer Chemother Pharmacol; 2010 May; 65(6):1153-63. PubMed ID: 19771432
    [Abstract] [Full Text] [Related]

  • 8. Prediction of chemosensitivity using multigene analysis in head and neck squamous cell carcinoma.
    Hasegawa Y, Goto M, Hanai N, Ijichi K, Terada A, Hyodo I, Ogawa T, Fukushima M.
    Oncology; 2007 May; 73(1-2):104-11. PubMed ID: 18337622
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer.
    Hasegawa Y, Goto M, Hanai N, Ijichi K, Adachi M, Terada A, Hyodo I, Ogawa T, Furukawa T.
    Oral Oncol; 2007 Sep; 43(8):749-56. PubMed ID: 17112769
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cell viability assay for drug testing in ovarian cancer: in vitro kill versus clinical response.
    Ness RB, Wisniewski SR, Eng H, Christopherson W.
    Anticancer Res; 2002 Sep; 22(2B):1145-9. PubMed ID: 12168915
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Targeting cancer stem cells for more effective therapies: Taking out cancer's locomotive engine.
    Winquist RJ, Boucher DM, Wood M, Furey BF.
    Biochem Pharmacol; 2009 Aug 15; 78(4):326-34. PubMed ID: 19539800
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pharmacologic validation of human tumor clonogenic assays based on pleiotropic drug resistance: implications for individualized chemotherapy and new drug screening programs.
    Parchment RE, Soleimanpour K, Petrose S, Murphy MJ.
    Int J Cell Cloning; 1992 Nov 15; 10(6):359-68. PubMed ID: 1334113
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.